KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2025)

Ginkgo Bioworks Holdings' Share-based Compensation history spans 6 years, with the latest figure at $21.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 2.27% year-over-year to $21.0 million; the TTM value through Dec 2025 reached $82.1 million, down 27.73%, while the annual FY2025 figure was $81.5 million, 27.41% down from the prior year.
  • Share-based Compensation reached $21.0 million in Q4 2025 per DNA's latest filing, up from $18.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.6 billion in Q4 2021 to a low of $118000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $198.2 million, with a median of $39.5 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: skyrocketed 1348422.03% in 2021, then plummeted 93.2% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $1.6 billion in 2021, then tumbled by 93.2% to $108.2 million in 2022, then plummeted by 60.4% to $42.8 million in 2023, then crashed by 52.0% to $20.6 million in 2024, then rose by 2.27% to $21.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Share-based Compensation are $21.0 million (Q4 2025), $18.1 million (Q3 2025), and $22.5 million (Q2 2025).